RTW Investments LP Has $238.86 Million Stock Position in Insmed Incorporated (NASDAQ:INSM)

RTW Investments LP reduced its position in Insmed Incorporated (NASDAQ:INSM - Free Report) by 10.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,272,008 shares of the biopharmaceutical company's stock after selling 368,100 shares during the quarter. Insmed makes up 3.5% of RTW Investments LP's portfolio, making the stock its 11th largest holding. RTW Investments LP owned approximately 1.83% of Insmed worth $238,857,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Nisa Investment Advisors LLC boosted its stake in Insmed by 8.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,778 shares of the biopharmaceutical company's stock valued at $119,000 after buying an additional 135 shares in the last quarter. CIBC Asset Management Inc lifted its holdings in shares of Insmed by 3.5% during the third quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company's stock valued at $324,000 after acquiring an additional 149 shares during the period. CWM LLC boosted its stake in shares of Insmed by 11.0% in the 2nd quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company's stock valued at $105,000 after purchasing an additional 155 shares in the last quarter. Commerce Bank increased its position in shares of Insmed by 2.4% during the 3rd quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company's stock worth $499,000 after purchasing an additional 163 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in Insmed by 71.3% during the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 224 shares during the last quarter.

Insiders Place Their Bets

In related news, insider Martina M.D. Flammer sold 13,436 shares of the company's stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the completion of the sale, the insider now owns 106,134 shares in the company, valued at $7,951,559.28. This represents a 11.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of Insmed stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total value of $2,686,612.50. Following the transaction, the insider now owns 100,100 shares in the company, valued at approximately $7,157,150. This represents a 27.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 78,882 shares of company stock worth $5,765,446. Insiders own 4.60% of the company's stock.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Bank of America upped their price objective on shares of Insmed from $84.00 to $86.00 and gave the stock a "buy" rating in a research note on Wednesday, October 9th. Stifel Nicolaus raised their price target on Insmed from $74.00 to $88.00 and gave the company a "buy" rating in a report on Friday, August 9th. Cantor Fitzgerald reissued an "overweight" rating on shares of Insmed in a research note on Monday, September 9th. JPMorgan Chase & Co. raised their target price on Insmed from $74.00 to $83.00 and gave the company an "overweight" rating in a research note on Friday, November 22nd. Finally, Truist Financial reaffirmed a "buy" rating and issued a $105.00 price target (up from $100.00) on shares of Insmed in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, Insmed presently has an average rating of "Moderate Buy" and an average price target of $83.67.

Insmed Trading Down 0.0 %

INSM stock traded down $0.03 during midday trading on Thursday, reaching $75.33. The company's stock had a trading volume of 2,244,301 shares, compared to its average volume of 2,215,028. The business's 50-day simple moving average is $72.31 and its 200-day simple moving average is $69.10. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $80.53. The stock has a market cap of $13.48 billion, a PE ratio of -13.57 and a beta of 1.10.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. The firm's revenue was up 18.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.10) EPS. As a group, sell-side analysts expect that Insmed Incorporated will post -5.44 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.